Investors
Best-in-Class Treatment for DDD
Notogen presents a unique opportunity to invest in the expansive spine, orthopedic and sports medicine therapeutic technology space. A profound void exists in the continuum of care related to non-surgical intervention for back pain. NTG-101 is positioned to address this void with a simple, cost-effective solution. Notogen has secured investment to achieve near-term goals and is currently seeking additional investment to support future milestones.
Events & Presentations
Oct
2018
19
Chicago, IL
2018 Biologic: Interventions for Spinal Pathologies: Stem Cells, Growth Factors & Novel Therapeutics
2018 Biologic: Interventions for Spinal Pathologies: Stem Cells, Growth Factors & Novel Therapeutics
Sep
2018
26
Los Angeles, CA
North American Spine Society (NASS) 33rd Annual Meeting
North American Spine Society (NASS) 33rd Annual Meeting
Nov
2017
04
Toronto, ON
LLC 5th Annual Ehlers-Danlos & Chronic Pain Conference
LLC 5th Annual Ehlers-Danlos & Chronic Pain Conference
Oct
2017
25
Orlando, FL
North American Spine Society (NASS) Conference 2017
North American Spine Society (NASS) Conference 2017
Oct
2016
26
Boston, MA
North American Spine Society (NASS) Conference 2016
North American Spine Society (NASS) Conference 2016
News Releases
Nov
2018
19
Notogen Appoints Gary Margolis as New Chief Executive Officer
Nov
2018
14
Therapeutic Potential of NTG-101, a Single Dose Injectable Treatment for Degenerative Disc Disease, Demonstrated in Preclinical Large Animal Study Published in Nature Publishing Group's “Scientific Reports”
Oct
2017
25
Best Papers Focus on Disc Regeneration, Pelvic Incidence
Mar
2017
22
One step closer to halting the “relentless cascade” of disc degeneration
Dec
2015
01
PUBLISHED: The biological basis of degenerative disc disease: proteomic and biomechanical analysis of the canine intervertebral disc